<DOC>
	<DOCNO>NCT02273258</DOCNO>
	<brief_summary>Primary Objective : To compare exposure activity SAR342434 US-approved EU-approved Humalog® . Secondary Objective : To assess safety tolerability SAR342434 .</brief_summary>
	<brief_title>A Study Compare Pharmacokinetics Pharmacodynamics SAR342434 Insulin Lispro Subjects With Type 1 Diabetes</brief_title>
	<detailed_description>The total study duration screen subject 3 - 8 week ( min-max duration , excl . screen ) - Screening : 2 28 day ( D -28 D -2 ) - Treatment period 1 - 3 : 2 day ( 1 overnight stay ) - Washout : 5 - 18 day ( preferentially 7 day consecutive dosing ) - End-of-study visit : 1 day D 5 D14 last administration investigational product .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Lispro</mesh_term>
	<criteria>Inclusion criterion : Male female subject diabetes mellitus type 1 one year . Total insulin dose &lt; 1.2 U/kg/day . Fasting negative serum Cpeptide ( &lt; 0.3 nmol/L ) . Glycohemoglobin ( HbA1c ) ≤ 9 % . Stable insulin regimen least 2 month prior study . Normal find medical history physical examination ( cardiovascular system , chest lung , thyroid , abdomen , nervous system , skin mucosa , musculoskeletal system ) , vital sign , electrocardiogram ( ECG ) safety lab . Exclusion criterion : Any history presence clinically relevant cardiovascular , pulmonary , gastrointestinal , hepatic , renal , metabolic ( apart diabetes mellitus type 1 ) , hematological , neurological , osteomuscular , articular , psychiatric , systemic , ocular , infectious disease , sign acute illness . More one episode severe hypoglycemia seizure , coma require assistance another person past 6 month . Frequent headache and/or migraine , recurrent nausea and/or vomit ( twice month . Symptomatic postural hypotension , irrespective decrease blood pressure , asymptomatic postural hypotension define decrease systolic blood pressure ≥20 mmHg within 3 minute change supine stand position . Presence history drug hypersensitivity , allergic disease diagnose treated physician . Likelihood require treatment study period drug permit clinical study protocol . Any medication ( include St John 's Wort ) within 14 day inclusion within 5 time elimination halflife pharmacodynamic halflife medication , exception insulin , thyroid hormone , lipidlowering antihypertensive drug female exception hormonal contraception menopausal hormone replacement therapy ; vaccination within last 28 day . Positive result follow test : hepatitis B surface ( HBs Ag ) antigen , antihepatitis C virus ( antiHCV ) antibody , antihuman immunodeficiency virus 1 2 antibody ( antiHIV1 anti HIV2 Ab . Any history presence deep leg vein thrombosis frequent appearance deep leg vein thrombosis 1st degree relative ( parent , sibling child ) . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>